NCT02038920 is a Phase 3 clinical trial of Vedolizumab in Crohn's Disease, sponsored by Takeda.

Who is sponsoring NCT02038920?

NCT02038920 is sponsored by Takeda.

What drugs are being tested in NCT02038920?

Interventions in NCT02038920: Vedolizumab, Vedolizumab placebo.

What condition does NCT02038920 study?

NCT02038920 studies Crohn's Disease.

Is NCT02038920 still recruiting?

NCT02038920 is currently completed. Last updated 9 December 2019.

Are results published for NCT02038920?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2019-12-09 · How we verify

NCT02038920

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Phase III Study of MLN0002 (300 mg) in Treatment of Crohn's Disease

Completed Phase 3 Results posted Last updated 9 December 2019

What this trial tests

Phase 3 trial testing Vedolizumab in Crohn's Disease in 157 participants. Completed in 21 May 2019.

Timeline

28 January 2014

Primary endpoint
25 January 2019

21 May 2019

Quick facts

Lead sponsor	Takeda
Phase	Phase 3
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	157
Start date	28 January 2014
Primary completion	25 January 2019
Estimated completion	21 May 2019
Sites	56 locations across Japan

Drugs / interventions tested

Vedolizumab (vedolizumab) — full drug profile →
Vedolizumab placebo — full drug profile →

Conditions studied

Crohn's Disease — all drugs for Crohn's Disease →

Sponsor

Takeda — full company profile →

Who can join

Adults 15 to 80, any sex, with Crohn's Disease. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Induction Phase: Percentage of Participants With Crohn's Disease Activity Index (CDAI)-100 Response Primary · Week 10

A response to therapy is considered a decrease from baseline of at least 100 points in the CDAI score at Week 10. CDAI is scoring system for the assessment of Crohn's disease activity. The total CDAI score ranges from 0 to approximately 600, where higher scores indicate more severe disease. Index values of 150 and below are associated with quiescent disease; values above that indicate active disease.

Group	Value	95% CI
Induction Phase: Vedolizumab, 300 mg	26.6	17.268 – 37.720
Induction Phase: Placebo	16.7	9.184 – 26.813

Maintenance Phase: Percentage of Participants With Clinical Remission Primary · Week 60

Clinical remission is defined as the CDAI score ≤150. CDAI is scoring system for the assessment of Crohn's disease activity. Index values of 150 and below are associated with quiescent disease; values above that indicate active disease.

Group	Value	95% CI
Maintenance Phase: Vedolizumab 300 mg	41.7	15.165 – 72.333
Maintenance Phase: Placebo	16.7	2.086 – 48.414

Number of Participants Who Experienced at Least One or More Treatment-Emergent Adverse Events (TEAEs) Primary · From Baseline up to 16 weeks after the last dose of study drug (Up to approximately 170 weeks)

An Adverse event (AE) is defined as any untoward medical occurrence in a study participant who received a drug (including a study drug); it does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (e.g., a clinically significant abnormal laboratory finding), symptom, or disease temporally associated with the use of a drug whether or not it is considered related to the drug. A TEAE is defined as an adverse event with an onset that occurs after receiving study drug.

Group	Value	95% CI
Induction Phase: Vedolizumab, 300 mg	49
Induction Phase: Placebo	42
Maintenance Phase: Vedolizumab 300 mg	9
Maintenance Phase: Placebo	10
Maintenance Phase: Placebo Continuation	12
Open-Label: Vedolizumab 300 mg	130

Number of Participants With TEAE Related to Body Weight (Weight Decreased) Primary · From Baseline up to 16 weeks after the last dose of study drug (Up to approximately 170 weeks)

Reported events on this outcome measure were "Weight Decreased".

Group	Value	95% CI
Induction Phase: Vedolizumab, 300 mg	0
Induction Phase: Placebo	0
Maintenance Phase: Vedolizumab 300 mg	0
Maintenance Phase: Placebo	0
Maintenance Phase: Placebo Continuation	0
Open-Label: Vedolizumab 300 mg	2

Number of Participants With TEAE Related to Vital Signs Primary · From Baseline up to 16 weeks after the last dose of study drug (Up to approximately 170 weeks)

Vital signs included body temperature (axilla), sitting blood pressure (after the participant has rested for at least 5 minutes), and pulse (bpm). Reported events on this outcome measure were "Pyrexia", "Body temperature increased", "Hypertension", and "Orthostatic hypotension".

Pyrexia

Group	Value	95% CI
Induction Phase: Vedolizumab, 300 mg	3
Induction Phase: Placebo	1
Maintenance Phase: Vedolizumab 300 mg	0
Maintenance Phase: Placebo	1
Maintenance Phase: Placebo Continuation	1
Open-Label: Vedolizumab 300 mg	19

Body Temperature Increased

Group	Value	95% CI
Induction Phase: Vedolizumab, 300 mg	1
Induction Phase: Placebo	0
Maintenance Phase: Vedolizumab 300 mg	0
Maintenance Phase: Placebo	0
Maintenance Phase: Placebo Continuation	0
Open-Label: Vedolizumab 300 mg	0

Hypertension

Group	Value	95% CI
Induction Phase: Vedolizumab, 300 mg	0
Induction Phase: Placebo	0
Maintenance Phase: Vedolizumab 300 mg	1
Maintenance Phase: Placebo	0
Maintenance Phase: Placebo Continuation	0
Open-Label: Vedolizumab 300 mg	1

Orthostatic Hypotension

Group	Value	95% CI
Induction Phase: Vedolizumab, 300 mg	0
Induction Phase: Placebo	0
Maintenance Phase: Vedolizumab 300 mg	0
Maintenance Phase: Placebo	0
Maintenance Phase: Placebo Continuation	0
Open-Label: Vedolizumab 300 mg	1

Number of Participants With TEAE Related to Electrocardiogram (ECG) [Bundle Branch Block Right] Primary · From Baseline up to 16 weeks after the last dose of study drug (Up to approximately 170 weeks)

Reported events on this outcome measure were "Bundle Branch Block Right".

Group	Value	95% CI
Induction Phase: Vedolizumab, 300 mg	0
Induction Phase: Placebo	0
Maintenance Phase: Vedolizumab 300 mg	0
Maintenance Phase: Placebo	0
Maintenance Phase: Placebo Continuation	0
Open-Label: Vedolizumab 300 mg	1

Number of Participants With Markedly Abnormal Values of Laboratory Parameters Values Primary · From Baseline up to 16 weeks after the last dose of study drug (Up to approximately 170 weeks)

The laboratory values outside the range (Hemoglobin \<=7 g/dL, Lymphocytes \<500 /microL, White Blood Cell (WBC) \<2000 /microL, Platelets \<7.5 10\^4/microL, Neutrophils \<1000 /microL, Alanine Aminotransferase (ALT) (Glutamic Pyruvic Transaminase; GPT) \>3.0 U/L x upper limit of normal (ULN), Aspartate Aminotransferase (AST) (Glutamic Oxaloacetic Transaminase; GOT) \>3.0 U/L x ULN, Total Bilirubin \>2.0 mg/dL x ULN, Amylase \>2.0 (U/L) x ULN are considered markedly abnormal.

Hemoglobin (g/dL) <=7

Group	Value	95% CI
Induction Phase: Vedolizumab, 300 mg	0
Induction Phase: Placebo	1
Maintenance Phase: Vedolizumab 300 mg	0
Maintenance Phase: Placebo	0
Maintenance Phase: Placebo Continuation	0
Open-Label: Vedolizumab 300 mg	4

Lymphocytes (/uL) <500

Group	Value	95% CI
Induction Phase: Vedolizumab, 300 mg	7
Induction Phase: Placebo	6
Maintenance Phase: Vedolizumab 300 mg	1
Maintenance Phase: Placebo	2
Maintenance Phase: Placebo Continuation	1
Open-Label: Vedolizumab 300 mg	18

WBC (/uL) <2000

Group	Value	95% CI
Induction Phase: Vedolizumab, 300 mg	0
Induction Phase: Placebo	0
Maintenance Phase: Vedolizumab 300 mg	0
Maintenance Phase: Placebo	0
Maintenance Phase: Placebo Continuation	0
Open-Label: Vedolizumab 300 mg	1

Platelets (10^4/uL) <7.5

Group	Value	95% CI
Induction Phase: Vedolizumab, 300 mg	0
Induction Phase: Placebo	0
Maintenance Phase: Vedolizumab 300 mg	0
Maintenance Phase: Placebo	0
Maintenance Phase: Placebo Continuation	0
Open-Label: Vedolizumab 300 mg	1

Neutrophils (/uL) <1000

Group	Value	95% CI
Induction Phase: Vedolizumab, 300 mg	0
Induction Phase: Placebo	0
Maintenance Phase: Vedolizumab 300 mg	0
Maintenance Phase: Placebo	0
Maintenance Phase: Placebo Continuation	0
Open-Label: Vedolizumab 300 mg	1

ALT (GPT) (U/L) >3.0 x ULN

Group	Value	95% CI
Induction Phase: Vedolizumab, 300 mg	1
Induction Phase: Placebo	1
Maintenance Phase: Vedolizumab 300 mg	0
Maintenance Phase: Placebo	0
Maintenance Phase: Placebo Continuation	0
Open-Label: Vedolizumab 300 mg	1

AST (GOT) (U/L) >3.0 x ULN

Group	Value	95% CI
Induction Phase: Vedolizumab, 300 mg	1
Induction Phase: Placebo	0
Maintenance Phase: Vedolizumab 300 mg	0
Maintenance Phase: Placebo	0
Maintenance Phase: Placebo Continuation	0
Open-Label: Vedolizumab 300 mg	1

Total Bilirubin (mg/dL) >2.0 x ULN

Group	Value	95% CI
Induction Phase: Vedolizumab, 300 mg	0
Induction Phase: Placebo	0
Maintenance Phase: Vedolizumab 300 mg	0
Maintenance Phase: Placebo	0
Maintenance Phase: Placebo Continuation	0
Open-Label: Vedolizumab 300 mg	4

Induction Phase: Percentage of Participants With Clinical Remission Secondary · Week 10

Group	Value	95% CI
Induction Phase: Vedolizumab, 300 mg	17.7	10.041 – 27.942
Induction Phase: Placebo	10.3	4.533 – 19.213

Induction Phase: Change From Baseline in C-reactive Protein (CRP) Values Secondary · Baseline to Week 10

Change from Baseline at Week 2

Group	Value	95% CI
Induction Phase: Vedolizumab, 300 mg	0.022	± 2.1421
Induction Phase: Placebo	-0.125	± 2.8417

Change from Baseline at Week 6

Group	Value	95% CI
Induction Phase: Vedolizumab, 300 mg	-0.089	± 2.0266
Induction Phase: Placebo	0.130	± 2.1674

Change from Baseline at Week 10

Group	Value	95% CI
Induction Phase: Vedolizumab, 300 mg	-0.164	± 2.2729
Induction Phase: Placebo	0.077	± 2.8690

Maintenance Phase: Percentage of Participants With Crohn's Disease Activity Index (CDAI)-100 Response Secondary · Week 60

Group	Value	95% CI
Maintenance Phase: Vedolizumab 300 mg	58.3	27.667 – 84.835
Maintenance Phase: Placebo	8.3	0.211 – 38.480

Maintenance Phase: Percentage of Participants With Durable Clinical Remission Secondary · From Week 14 and Week 60

Durable clinical remission is defined as participants with CDAI score ≤ 150 at both Weeks 14 and 60. CDAI is scoring system for the assessment of Crohn's disease activity. The total CDAI score ranges from 0 to approximately 600, where higher scores indicate more severe disease. Index values of 150 and below are associated with quiescent disease; values above that indicate active disease.

Group	Value	95% CI
Maintenance Phase: Vedolizumab 300 mg	33.3	9.925 – 65.112
Maintenance Phase: Placebo	25.0	5.486 – 57.186

Maintenance Phase: Percentage of Participants With Corticosteroid-free Clinical Remission Secondary · Week 60

Corticosteroid-free clinical remission is defined as participants using oral corticosteroids at baseline (Week 0) who discontinued corticosteroids and were in clinical remission (CDAI score ≤ 150) at Week 60. CDAI is scoring system for the assessment of Crohn's disease activity. The total CDAI score ranges from 0 to approximately 600, where higher scores indicate more severe disease. Index values of 150 and below are associated with quiescent disease; values above that indicate active disease.

Group	Value	95% CI
Maintenance Phase: Vedolizumab 300 mg	40.0	5.274 – 85.337
Maintenance Phase: Placebo	0.0	0.000 – 70.760

Adverse events — posted to ClinicalTrials.gov

Time frame: From Baseline up to 16 weeks after the last dose of study drug (Up to approximately 170 weeks). Reporting threshold: 5%. Adverse-event reports describe events observed during the trial — not all are caused by the drug.

Induction Phase: Vedolizumab, 300 mg

Serious: 8/79 (10%)

Deaths: 0/79

Induction Phase: Placebo

Serious: 10/78 (13%)

Deaths: 0/78

Maintenance Phase: Vedolizumab 300 mg

Serious: 2/12 (17%)

Deaths: 0/12

Maintenance Phase: Placebo

Serious: 4/12 (33%)

Deaths: 0/12

Maintenance Phase: Placebo Continuation

Serious: 2/17 (12%)

Deaths: 0/17

Open-Label: Vedolizumab 300 mg

Serious: 70/134 (52%)

Deaths: 0/134

Serious adverse events (53 terms)

Reaction	System	Induction Phase: Vedolizum…	Induction Phase: Placebo	Maintenance Phase: Vedoliz…	Maintenance Phase: Placebo	Maintenance Phase: Placebo…	Open-Label: Vedolizumab 30…
Crohn's disease	Gastrointestinal disorders	—	—	—	—	—	—
Intestinal obstruction	Gastrointestinal disorders	—	—	—	—	—	—
Anal abscess	Infections and infestations	—	—	—	—	—	—
Ileus	Gastrointestinal disorders	—	—	—	—	—	—
Intestinal stenosis	Gastrointestinal disorders	—	—	—	—	—	—
Anal fistula	Gastrointestinal disorders	—	—	—	—	—	—
Abdominal abscess	Infections and infestations	—	—	—	—	—	—
Enteritis infectious	Infections and infestations	—	—	—	—	—	—
Ascites	Gastrointestinal disorders	—	—	—	—	—	—
Subileus	Gastrointestinal disorders	—	—	—	—	—	—
Hepatic function abnormal	Hepatobiliary disorders	—	—	—	—	—	—
Anaphylactoid reaction	Immune system disorders	—	—	—	—	—	—
Gastroenteritis viral	Infections and infestations	—	—	—	—	—	—
Dehydration	Metabolism and nutrition disorders	—	—	—	—	—	—
Thyroid adenoma	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	—	—	—	—	—	—
Abdominal adhesions	Gastrointestinal disorders	—	—	—	—	—	—
Cellulitis	Infections and infestations	—	—	—	—	—	—
Erythema nodosum	Skin and subcutaneous tissue disorders	—	—	—	—	—	—
Abdominal pain	Gastrointestinal disorders	—	—	—	—	—	—
Enterovesical fistula	Gastrointestinal disorders	—	—	—	—	—	—
Gastrointestinal haemorrhage	Gastrointestinal disorders	—	—	—	—	—	—
Ileal stenosis	Gastrointestinal disorders	—	—	—	—	—	—
Intestinal perforation	Gastrointestinal disorders	—	—	—	—	—	—
Large intestinal stenosis	Gastrointestinal disorders	—	—	—	—	—	—
Large intestine perforation	Gastrointestinal disorders	—	—	—	—	—	—

Other adverse events (48 terms — click to expand)

Reaction	System	Induction Phase: Vedolizum…	Induction Phase: Placebo	Maintenance Phase: Vedoliz…	Maintenance Phase: Placebo	Maintenance Phase: Placebo…	Open-Label: Vedolizumab 30…
Nasopharyngitis	Infections and infestations	—	—	—	—	—	—
Crohn's disease	Gastrointestinal disorders	—	—	—	—	—	—
Pyrexia	General disorders	—	—	—	—	—	—
Influenza	Infections and infestations	—	—	—	—	—	—
Dental caries	Gastrointestinal disorders	—	—	—	—	—	—
Anaemia	Blood and lymphatic system disorders	—	—	—	—	—	—
Nausea	Gastrointestinal disorders	—	—	—	—	—	—
Upper respiratory tract infection	Infections and infestations	—	—	—	—	—	—
Hepatic function abnormal	Hepatobiliary disorders	—	—	—	—	—	—
Headache	Nervous system disorders	—	—	—	—	—	—
Abdominal pain upper	Gastrointestinal disorders	—	—	—	—	—	—
Insomnia	Psychiatric disorders	—	—	—	—	—	—
Gastroenteritis	Infections and infestations	—	—	—	—	—	—
Back pain	Musculoskeletal and connective tissue disorders	—	—	—	—	—	—
Pharyngitis	Infections and infestations	—	—	—	—	—	—
Enteritis infectious	Infections and infestations	—	—	—	—	—	—
Hypoaesthesia	Nervous system disorders	—	—	—	—	—	—
Conjunctivitis	Infections and infestations	—	—	—	—	—	—
Iron deficiency anaemia	Blood and lymphatic system disorders	—	—	—	—	—	—
Diarrhoea	Gastrointestinal disorders	—	—	—	—	—	—
Abdominal pain	Gastrointestinal disorders	—	—	—	—	—	—
Constipation	Gastrointestinal disorders	—	—	—	—	—	—
Gastrooesophageal reflux disease	Gastrointestinal disorders	—	—	—	—	—	—
Stomatitis	Gastrointestinal disorders	—	—	—	—	—	—
Chest pain	General disorders	—	—	—	—	—	—
Swelling	General disorders	—	—	—	—	—	—
Allergy to metals	Immune system disorders	—	—	—	—	—	—
Seasonal allergy	Immune system disorders	—	—	—	—	—	—
Anal abscess	Infections and infestations	—	—	—	—	—	—
Dermatophytosis of nail	Infections and infestations	—	—	—	—	—	—
Pharyngotonsillitis	Infections and infestations	—	—	—	—	—	—
Rhinitis	Infections and infestations	—	—	—	—	—	—
Tonsillitis	Infections and infestations	—	—	—	—	—	—
Bone contusion	Injury, poisoning and procedural complications	—	—	—	—	—	—
Heat illness	Injury, poisoning and procedural complications	—	—	—	—	—	—
Blood urine present	Investigations	—	—	—	—	—	—
Glucose urine present	Investigations	—	—	—	—	—	—
Ocular neoplasm	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	—	—	—	—	—	—
Skin papilloma	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	—	—	—	—	—	—
Cervicobrachial syndrome	Nervous system disorders	—	—	—	—	—	—

Most-reported serious reactions: Crohn's disease, Intestinal obstruction, Anal abscess, Ileus, Intestinal stenosis, Anal fistula, Abdominal abscess, Enteritis infectious.

Data from ClinicalTrials.gov NCT02038920 adverse events section.

Sponsor's own description

This study is a phase 3, multicenter, randomized, double-blinded, placebo-controlled, parallel-group study to examine the efficacy, safety, and pharmacokinetics of vedolizumab (MLN0002) in induction and maintenance therapy in Japanese participants with moderately or severely active Crohn's disease.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Immunology of Inflammatory Bowel Disease: Molecular Mechanisms and Therapeutics.
Lu Q, Yang MF, Liang YJ, Xu J, et al · · 2022 · cited 152× · PMID 35310454 · DOI 10.2147/jir.s353038
Vedolizumab: an α4β7 integrin antagonist for ulcerative colitis and Crohn's disease.
Cherry LN, Yunker NS, Lambert ER, Vaughan D, et al · · 2015 · cited 43× · PMID 26336591 · DOI 10.1177/2040622315586970
Effects of vedolizumab in Japanese patients with Crohn's disease: a prospective, multicenter, randomized, placebo-controlled Phase 3 trial with exploratory analyses.
Watanabe K, Motoya S, Ogata H, Kanai T, et al · · 2020 · cited 39× · PMID 31836930 · DOI 10.1007/s00535-019-01647-w
Population pharmacokinetics of vedolizumab in Asian and non-Asian patients with ulcerative colitis and Crohn's disease.
Okamoto H, Dirks NL, Rosario M, Hori T, et al · · 2021 · cited 23× · PMID 32635680 · DOI 10.5217/ir.2019.09167
Placebo Rates in Crohn's Disease Randomized Clinical Trials: An Individual Patient Data Meta-Analysis.
Solitano V, Hogan M, Singh S, Danese S, et al · · 2025 · cited 11× · PMID 39414161 · DOI 10.1053/j.gastro.2024.10.009
Designing biologic selectivity for inflammatory bowel disease--role of vedolizumab.
Krupka N, Baumgart DC. · · 2015 · cited 11× · PMID 25552903 · DOI 10.2147/dddt.s50348
Comparative Efficacy of Subcutaneous and Intravenous Infliximab and Vedolizumab for Maintenance Treatment of TNF-naive Adult Patients with Inflammatory Bowel Disease: A Systematic Literature Review and Network Meta-analysis.
Peyrin-Biroulet L, Bossuyt P, Bettenworth D, Loftus EV, et al · · 2024 · cited 10× · PMID 38499736 · DOI 10.1007/s10620-023-08252-1
Defining the Failure of Medical Therapy for Inflammatory Bowel Disease in the Era of Advanced Therapies: A Systematic Review.
State M, Negreanu L. · · 2023 · cited 10× · PMID 36831079 · DOI 10.3390/biomedicines11020544

Verify or expand the search:

Other trials of Vedolizumab

Trials testing the same drug.

NCT06646016 — EPIC- Extracorporeal Photopheresis (ECP) for Immune-related Colitis · Phase 2 · withdrawn
NCT06815003 — Vedolizumab Plus Post-transplant Cyclophosphamide and Short Course Tacrolimus for the Prevention of Graft Versus Host Di · Phase 2 · recruiting
NCT06227910 — A Study of Vedolizumab With and Without Upadacitinib in Adults With Crohn's Disease · Phase 3 · recruiting
NCT06443502 — A Study to Learn About the Safety of Vedolizumab and How Well it Works in Children and Teenagers With Active Chronic Pou · Phase 3 · recruiting
NCT06570772 — Study to Investigate Comparative Efficacy, Safety and Immunogenicity Between AVT16 and Entyvio · Phase 3 · terminated

Other recruiting trials for Crohn's Disease

Currently open trials in the same condition.

NCT07273188 — 68Ga-FAPI-46 PET/CT for Assessing Small Bowel Fibrostenosis in Crohn's Disease · EARLY_PHASE1 · recruiting
NCT07184944 — A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Acti · Phase 3 · recruiting
NCT07242248 — A Study to Observe Real-world Evidence of Guselkumab Treatment in Participants With Ulcerative Colitis and Crohn's Disea · recruiting
NCT06405087 — A Long-Term Extension Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis (UC) or Crohn's Disease (CD · Phase 3 · recruiting
NCT07184931 — An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Activ · Phase 3 · recruiting

Other Takeda trials

Trials by the same sponsor.

NCT05669729 — A Survey to Assess Participants', Caregivers', and Nurses' Use and Understanding of Educational Material on Velagluceras · not yet recruiting
NCT07403968 — A Study of Zasocitinib (TAK-279) in Adults With Active Crohn's Disease · Phase 2 · not yet recruiting
NCT07293364 — A Study to Learn About the C1-Inhibitor Function as Diagnosis for Hereditary Angioedema · NA · not yet recruiting
NCT07218393 — A Study About the Diagnosis and Management of Hereditary Angioedema (HAE) in Egypt · not yet recruiting
NCT07445087 — A Study of Takhzyro in Teenagers and Adults With Hereditary Angioedema (HAE) in South Korea · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02038920 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Takeda
Last refreshed: 9 December 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02038920.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing